about
P108
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone TherapySitravatinib and Nivolumab in Urothelial Carcinoma StudySafety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic LeukemiaA Study of Intravenous XMT-1001 in Patients With Advanced Solid TumorsExpanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)Efficacy and Safety of LBH589B in Adult Patients With Multiple MyelomaA Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive TumorsIxabepilone + Carboplatin Metastatic Breast CancerStudy to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic ProfileA Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple MyelomaA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerPersonalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With LymphomaA Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerPhase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsVelcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and PrednisoneA Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaStudy of TPI 287 in Patients With Advanced MalignanciesStudy of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsVaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's LymphomaMobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma PatientsMobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma PatientsVaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's LymphomaGemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer PatientsStudy Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple MyelomaMarimastat in Treating Patients With Stage III Non-small Cell Lung CancerAmifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung CancerProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate CancerMelphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple MyelomaA Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung CancerA Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116The BEACON Study (Breast Cancer Outcomes With NKTR-102)PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell CarcinomaComparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell TransplantDiet Composition, Weight Control, and Breast Carcinogenesis
P6153
Q58848980-786A22EE-B4BF-4EA8-8261-AFA33ED02C86Q61907246-5796A5EA-A106-46F0-9A4D-F99DBB2262B2Q61917597-B51100CA-5086-4FC0-81B0-43CAF3BE1E3EQ61920661-11FA9B2D-A2A9-41F3-9382-3821BC907EBEQ61921025-E4CF6BC2-3CC9-4EEC-B3F5-433FC9B2CECFQ61921134-68953AD3-63C2-4DE4-A471-9DA8ECEF556CQ61924660-D68229DA-86E1-4A31-9CCF-E031F7BAEBDDQ61932758-AAD8904E-1A61-48E2-868E-5248836F32ECQ61932780-64DBA638-9C22-49FD-9006-751B16C24863Q61938275-2DE72597-8E3C-465D-A38C-B05C195C1A0AQ61938484-698B2F03-8366-4DCE-94F0-C6831AC38F24Q61966605-55256372-E735-41E0-A665-1275524704D7Q61969377-8BD72EE7-F8DA-47B1-A2A2-815C062A30E4Q61975530-611DB732-6F0F-4AF2-A333-BBD6C440FB71Q61979213-D2D08235-E596-4B7F-AC3F-C65FD7E08241Q61979350-61AD9D75-2300-4029-84A3-429BCED9B2E1Q61979801-4948BB6F-9298-4030-A666-2D6ECCA8BD39Q61979804-528ACD80-83D4-479C-8ECB-67E5A368E79FQ61980275-45C3A477-8C88-462A-9F54-0FCF62A39459Q61981018-53B71822-9311-4DAC-A21E-E9FCCFF00194Q62104894-93A02603-54C7-4C1F-957C-C046E7FBB4C4Q62105276-7ED66900-9BD7-4F39-A6AD-D7771ACA5923Q62105834-DEAD6684-4033-47B4-B4DA-F701D1958842Q62105945-230C3FDC-6E9B-4097-AEC7-15F094D0501CQ62105958-40FE6433-27E5-4B55-BA16-45561D9B3534Q62110090-4048B79F-9169-41B3-B1DD-D5956BC4FBCDQ62110359-7B52F346-68C4-4CCF-85CF-55C21DAF56DBQ62110630-1575AEAE-C952-43F5-90B6-4E20D9D35236Q62110897-08135BB9-2683-483F-83E1-8520219FB239Q62110939-A3D11164-236F-48A1-A2D4-380FF2C42CEAQ62110956-CEFDDBE2-71D4-4420-9999-87A3E3725849Q62811412-8DEB6DD9-BB42-4DAE-9EDE-7FD306D72D29Q63062499-7AF14F54-764F-4355-8766-FB7B34A29775Q63063081-1B9693A7-496C-4407-BC65-85EBD42C9624Q63319496-71719D48-8BEE-4308-98D4-45C9DFA4C840Q63319566-8076B704-A801-4292-8E97-4F3B785DB256Q63320307-FF7048DA-AAAE-43EE-9AEB-3D870580D468Q63322337-0E9528F8-FA46-4C93-85A1-91FDF641BDF4Q63336168-B3A1E28D-12CF-4B00-A847-335C4337610EQ63338341-FF4DBF0A-331B-4016-95FC-4035BE1A0B06
P6153
description
healthcare organization in Denver, United States
@en
name
Rocky Mountain Cancer Centers
@en
type
label
Rocky Mountain Cancer Centers
@en
altLabel
RMCC
@en
prefLabel
Rocky Mountain Cancer Centers
@en
P131
P213
0000 0004 0446 331X
P2427
grid.477771.5
P3500
P625
Point (-104.932059 39.732628)